Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.

Cardiol Therapeutics Inc.

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

Content Delivery Network

WordPress

Chief Medical Officer

Andrew Hamer

Chief Operating Officer

Bernard Lim

Founder, Advisory Analyst

Jenn Chao

Vice President Business Development

John Geddes

Senior Director, Clinical Operations

Andrea Parker

Engineering

Anthony Bolton

Blagoja Ristevski, CHE

Finance and Administration

Dan Crandall, CPA, CA

Director of Information Technology

Mary Hughes

Barbara Zibotics

Teri loxam

David Elsley

President & CEO

Trevor Burns

Investor Relations

Thomas Moffatt

Chief Commercial Officer

Biotechnology Companies With Less Than $10M in Revenue (Top 10K)

Great Lakes Companies With Less Than $500M in Revenue (Top 10K)

Biotechnology Companies With Less Than $50M in Revenue (Top 10K)

Ontario Public Companies With More Than 10 Employees

Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure.

Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.

Post-IPO Equity - Cardiol Therapeutics

Canaccord Genuity Group

Convertible Note - Cardiol Therapeutics

Seed Round - Cardiol Therapeutics

Oakville

Ontario

Canada

North America

Cardiol Therapeutics

Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today

Cardiol Therapeutics stock gets buy rating

Closing Bell: Cardiol Therapeutics Inc Purchase WT flat on Friday (CRDL-WT-A)

Cardiol Therapeutics shares fall after primary endpoint data from MAvERIC-Pilot

Cardiol Therapeutics Inc. (CRDL) Stock

Cardiol stock slips after CardiolRx trial data (NASDAQ:CRDL)

Canaccord Genuity ups Cardiol Therapeutics shares target citing positive trial outlook By Investing.com

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Cardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditis

United States

United Kingdom

Europe

France

Ecuador

South America

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 23, 2024 5:22 AM	34de29bb
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 23, 2024 5:22 AM	754c8e61
crunchbase trigger	general	Nov 4, 2024 10:53 AM	84ef6836
crunchbase profile	general	Nov 5, 2024 10:26 AM	5889256f
li profile	general
translate crunchbase fundingrounds	general	Nov 5, 2024 3:57 PM	4226f346
peers	general	Oct 23, 2024 5:22 AM	73ad31fc
news basic	general	Oct 23, 2024 5:22 AM	918cb370
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CARDIOLRX

Cardiol Therapeutics Inc.

Last Close

2.22

22/11 21:00

Market Cap

189.75M

Beta: -

Volume Today

109.83K

Avg: -